[Kim Sungjin, Edaily Reporter] South Korean pharmaceutical and biotechnology stocks posted mixed results on November 19, driven by clinical trial developments and expectations regarding their inclusion in major stock indices. Penetrium Bioscience surged following reports of encouraging results from an early-stage clinical trial of its prostate cancer drug candidate, while AprilBio gained on news of its inclusion in the KOSDAQ 150 index.
Meanwhile, stocks linked to AriBio moved in opposite directions. AriBio LAB extended its gains after hitting the daily upper price limit in the previous session, while ARIBIO Holdings declined. Although both companies are connected to AriBio’s oral Alzheimer’s disease drug candidate AR1001, differences in their corporate structures and business circumstances may have contributed to the divergence in investor sentiment.
Penetrium Bioscience Surges 17% on Prostate Cancer Trial Results
According to KG Zeroin’s MP Doctor, shares of Penetrium Bioscience closed at 6,750 won on November 19, up 17.19% from the previous session. The rally was attributed to positive investor sentiment following reports that patients receiving its prostate cancer drug candidate Penetrium (CP-PCA07) in combination with existing anticancer treatments showed encouraging responses in an early-stage clinical trial. Stock trend of Penetrium Bioscience. (Source: KG Zeroin) Hyundai Bioscience, the parent company of Penetrium Bioscience, announced that two patients who had developed resistance to existing anticancer therapies showed reductions in prostate-specific antigen (PSA) levels after receiving Penetrium in combination with conventional treatments during an ongoing Phase 1 clinical trial at Seoul National University Hospital.
The trial involves patients with metastatic castration-resistant prostate cancer. The findings were initially disclosed to shareholders in a notice issued on November 18.
Penetrium is being developed to restore treatment responses in patients who have developed resistance to existing anticancer drugs. A key concept behind Hyundai Bioscience Group’s development strategy is what the company calls “pseudo-resistance.”
This concept is based on the hypothesis that the tumor microenvironment can interfere with the activity of anticancer drugs. According to this theory, even when a drug retains its ability to attack cancer cells, structural barriers surrounding the tumor may prevent it from reaching or acting effectively on its target.
Hyundai Bioscience believes that repeated exposure to anticancer treatments can lead to changes in the tumor microenvironment that contribute to drug resistance. According to the company, physical barriers formed by hardened tissue surrounding cancer cells may restrict drug penetration even before genetic mutations associated with resistance emerge.
Penetrium is being developed to modify this environment and potentially enhance the effectiveness of existing anticancer therapies.
According to Hyundai Bioscience, patients who received Penetrium in combination with enzalutamide had previously shown reduced responses to conventional treatment. Following the addition of Penetrium, their PSA levels showed consecutive declines.
PSA is a blood-based biomarker commonly used to monitor disease progression and treatment responses in prostate cancer patients.
However, these findings should be interpreted with caution, as they are based on observations in only two patients at an early stage of clinical development. The results are not sufficient to establish the drug’s clinical efficacy.
Penetrium is also advancing its clinical development overseas. In September, the company received approval from the U.S. Food and Drug Administration (FDA) to proceed with a Phase 2a clinical trial involving patients with recurrent or refractory advanced solid tumors.
AprilBio Rises 14.67% Following Inclusion in the KOSDAQ 150 Index
AprilBio also posted strong gains on November 19, closing at 13,130 won, up 14.67% from the previous trading session.
The rally was largely attributed to news that the company would be added to the KOSDAQ 150 index.
On Nov. 18, the Korea Exchange announced the results of its regular review of constituents for major benchmark indices, including the KOSPI 200, KOSDAQ 150, and KRX 300.
AprilBio was among the companies newly selected for inclusion in the KOSDAQ 150. Other newly added pharmaceutical, biotechnology, and healthcare companies included Rznomics, LivsMed, Qurient, DongKook Pharmaceutical, and SEERS. AprilBio’s stock trend. (Source: KG Zeroin) The revised index composition will take effect on December 11.
Exchange-traded funds (ETFs) and index funds tracking the KOSDAQ 150 are required to adjust their portfolios in line with changes to the index’s constituents. As a result, newly included companies often attract investor interest amid expectations of additional passive fund inflows.
However, index inclusion does not necessarily guarantee sustained share price gains. The actual volume of passive investment depends on factors such as a stock’s weighting in the index and the total assets managed by index-tracking funds.
Investors must also consider the possibility that expectations surrounding index inclusion have already been factored into share prices.
AprilBio has recently faced uncertainties in its drug development programs.
In 2021, the company signed a licensing agreement worth up to $448 million with the Danish pharmaceutical company Lundbeck for APB-A1, an investigational treatment for autoimmune diseases.
However, in August, Lundbeck announced that it would discontinue development of APB-A1 for thyroid eye disease after clinical results failed to demonstrate the anticipated level of efficacy.
Nevertheless, Lundbeck has not entirely abandoned development of the drug candidate.
In its third-quarter earnings materials released on November 11, Lundbeck retained APB-A1, also known as Lu AG22515, in its Phase 1 pipeline and indicated that it was exploring further development opportunities in other neurological indications.
AprilBio has also outlined plans to pursue licensing deals for three new drug candidates.
At a research and development (R&D) event held on November 9, the company introduced three programs covering autoimmune diseases, metabolic disorders, and oncology.
APB-I-005 is a bispecific therapeutic candidate designed to simultaneously target TL1A and IL-23p19, two proteins associated with inflammatory bowel disease. The company plans to conduct preclinical toxicity studies next year.
APB-O-001, a small interfering RNA (siRNA) therapeutic candidate for metabolic diseases, is undergoing validation studies to confirm the efficacy of technology licensed from an external developer.
In oncology, AprilBio is developing APB-A-001, an antibody-drug conjugate (ADC) candidate designed to target both c-Met and VEGF.
"Today's rise in the share price appears to have been influenced by the company's inclusion in the KOSDAQ 150 index," an AprilBio official said.
AriBio LAB Rises While ARIBIO Holdings Falls Despite Shared Alzheimer’s Drug Exposure
Stocks associated with AriBio, which recently announced global Phase 3 clinical trial results for its oral Alzheimer’s disease drug candidate AR1001, continued to exhibit sharp volatility.
Following the release of top-line Phase 3 results on November 17, both AriBio LAB and ARIBIO Holdings suffered steep declines. AriBio LAB subsequently rebounded to the daily upper price limit on November 18, while ARIBIO Holdings recovered 21.68% in the same session. Stock trend of AriBio LAB (source: KG Zeroin) Their performances diverged on November 19.
AriBio LAB extended its gains, closing at 5,820 won, up approximately 10% from the previous session. In contrast, ARIBIO Holdings fell 4.33% to 2,980 won.
These contrasting performances have drawn attention to differences in the companies’ ownership structures and their respective positions within the AriBio Group.
ARIBIO Holdings, formerly listed under the name Sorux, had pursued a merger with privately held drug developer ARIBIO. However, the company abandoned the merger plan in September.
The proposed transaction had been seen as a potential pathway for ARIBIO to enter the KOSDAQ market. Its cancellation has created uncertainty regarding the group’s future ownership structure and listing strategy.
AriBio LAB, meanwhile, is undergoing a restructuring of its shareholder base through direct investment by ARIBIO.
In September, ARIBIO and ARIBIO Holdings agreed to invest a combined 18 billion won in AriBio LAB.
Under the arrangement, ARIBIO will contribute 15 billion won, while ARIBIO Holdings will invest 3 billion won.
If the capital injection scheduled for November 30 is completed as planned, ARIBIO will acquire a 15.9% stake in AriBio LAB, becoming its largest shareholder. Stock trend of ARIBIO Holdings (source: KG Zeroin) ARIBIO Holdings will become the second-largest shareholder with a 14.1% stake.
The transaction will shift AriBio LAB’s ownership structure from one led by ARIBIO Holdings to one in which privately held ARIBIO directly controls the listed biotechnology company.
Although the two companies share exposure to AR1001, their differing corporate positions and ownership arrangements present distinct investment considerations. The extent to which these structural differences contributed to their divergent share price movements remains unclear.
Just before Anthropic, the U.S. artificial intelligence (AI) developer behind “Clod,” went public on the Nasdaq, the iShares Bitcoin Trust (IBIT)—BlackRock’s iShares Bitcoin Trust, the largest Bitcoin…
Celltrion(068270)Forecasts indicate that Celltrion will continue its steep earnings growth as it expands its direct sales performance in the U.S. biosimilar market. Expectations for a revaluation of t…
South Korean pharmaceutical and biotechnology stocks posted mixed results on November 19, driven by clinical trial developments and expectations regarding their inclusion in major stock indices. Penet…